UPDATE: Bank of America Reiterates Buy Rating, Raises PT on AbbVie on Higher HCV Sales - AbbVie (NYSE:ABBV)

Crypto Whales Are Loading Up — Are You?

New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.

In a report published Friday, Bank of America analyst Gregg Gilbert reiterated a Buy rating on

Crypto Whales Are Loading Up — Are You?

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

AbbVie

(NYSE: ABBV), and raised the price target from $56.00 to $58.00.In the report, Bank of America noted, “ABBV is unique among the US Major Pharma companies given its significant product concentration (50% of 2012 revenues were generated by a single product, Humira). Despite this, we are bullish on ABBV given its attractive valuation, above-average dividend yield, and the potential for the pipeline to deliver a blockbuster HCV franchise over the medium term. We conservatively include no real contribution from the rest of the pipeline despite the fact that we continue to model robust R&D spend.”AbbVie closed on Thursday at $51.86.